Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.

PharmacoEconomics - 1 May 2013

Sorich Michael J, Wiese Michael D, O'Shea Rebekah L, Pekarsky Brita

Abstract excerpt

Hypercholesterolaemia is a highly prevalent condition that has major health and cost implications for society. Pharmacotherapy is an important and effective treatment modality for hypercholesterolaemia, with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ('statins') the most commonly used class of drugs. Over the past decade, there has been intensive research to identify pharmacogenetic markers to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol Ester Transfer Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypercholesterolemia

Share to Kinesins

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Source

Identifiers

PMID: 23568333
DOI: 10.1007/s40273-013-0045-6

Genes

ACE
CETP
KIF6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.PMID 23568333Read ↗

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.Semantic proximity Read ↗

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read ↗

Assessing the cost-effectiveness of pharmacogenomics.Semantic proximity Read ↗

Pharmacogenetics and cost-effectiveness analysis: a two-way street.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Semantic proximity Read ↗

Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.Semantic proximity Read ↗

An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.Semantic proximity Read ↗

Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.Semantic proximity Read ↗

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Semantic proximity Read ↗

Genetic screening by DNA technology: a systematic review of health economic evidence.Semantic proximity Read ↗

Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.Semantic proximity Read ↗

Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.